FN2 Earnings Intelligence

TG Therapeutics, Inc. analyst ratings

TG Therapeutics, Inc. (TGTX) analyst consensus, price targets, and firm-level rating history from FN2 Research.

Analyst Consensus ?

ConsensusBuy13 ratings
Bullish1184.6%
Neutral17.7%
Bearish17.7%

Analyst 52W Price Targets

$63.34Current
$11.5Low
$41Average
$83High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Evercore ISI Group Outperform OutperformMaintainNov 10, 2026
HC Wainwright & Co. Buy BuyMaintainSep 1, 2026
JP Morgan Overweight OverweightMaintainAug 7, 2026
B. Riley Securities Buy BuyMaintainJul 27, 2026
B of A Securities Underperform UnderperformMaintainJul 7, 2026
Show 8 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $63.34. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
H.C. WainwrightEmily Bodnar$78$46.17 +23.1%Aug 4, 2026
JefferiesAnalyst unavailable$83$54.4 +31.0%Jun 22, 2026
H.C. WainwrightAnalyst unavailable$70$39.75 +10.5%May 6, 2026
Goldman SachsAnalyst unavailable$39$29.54 -38.4%Jan 15, 2026
H.C. WainwrightEmily Bodnar$60$36.7 -5.3%Oct 6, 2025
See 8 more

Track every rating change on TGTX the moment it posts. Free to start.

Start free

Get the TGTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.